Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

NCT04393298 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04393298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04393298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
Lead sponsor
UCB Biopharma SRL
Phase
Phase 1/2
Overall status
Completed
Start date
July 9, 2020
Completion date
April 11, 2024
Enrollment
93 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors